Genzyme Corporation
|
500 Kendall Street
Cambridge, MA 02142
United States |
| Tel: |
1/617 252-7600 |
| URL: |
http://www.genzyme.com |
|
 |
| Primary Symbols & Exchanges: |
| GENZ - NASDAQ |
|
|
| Primary Industry: |
| Pharmaceutical |
|
|
SIC Industry Code:
|
|
NAICS Industry Code:
|
|
Thomson Financial Business Description:
| The Group's principal activities are to develop, manufacture and market biotechnology products. It operates through five segments: Therapeutics: Includes products for the treatment of genetic diseases and other chronic debilitating diseases. Renal: Consists of products for the treatment of renal diseases, including chronic renal failure. Biosurgery: Includes biotherapeutics and biomaterial products, with an emphasis on products that meet medical needs in orthopaedics and broader surgical areas. Genetics: Consists of vitro diagnostic products with an emphasis on point of care products for the in-hospital and out of hospital rapid test segment, clinical chemistry reagents and raw materials focused on the clinical laboratory. Transplant: Comprises of therapeutic products for the treatment of immune-mediated diseases. On 03-dec-2007, the group acquired Diagnostic Assets of Diagnostic Chemicals Limited. |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on Genzyme Corporation
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
